MX2010007462A - Metodos y composiciones para administracion oral de agentes terapeuticos de peptidos y proteinas. - Google Patents

Metodos y composiciones para administracion oral de agentes terapeuticos de peptidos y proteinas.

Info

Publication number
MX2010007462A
MX2010007462A MX2010007462A MX2010007462A MX2010007462A MX 2010007462 A MX2010007462 A MX 2010007462A MX 2010007462 A MX2010007462 A MX 2010007462A MX 2010007462 A MX2010007462 A MX 2010007462A MX 2010007462 A MX2010007462 A MX 2010007462A
Authority
MX
Mexico
Prior art keywords
protein
methods
compositions
oral administration
therapeutic agents
Prior art date
Application number
MX2010007462A
Other languages
English (en)
Inventor
Alexander Vol
Orna Gribova
Original Assignee
Oshadi Drug Administration Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oshadi Drug Administration Ltd filed Critical Oshadi Drug Administration Ltd
Publication of MX2010007462A publication Critical patent/MX2010007462A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona una composición farmacéutica formulada para administración oral, que comprende una mezcla asociada no covalentemente de material en partículas de nanopartículas de sílice farmacológicamente inertes, que tienen una superficie hidrófoba, un polisacárido, y una proteína o péptido biológicamente activos suspendidos en un aceite. La presente invención proporciona además, métodos para elaborar la misma y métodos terapéuticos que utilizan la misma para la administración oral de una proteína o péptido terapéuticos.
MX2010007462A 2008-01-08 2009-01-08 Metodos y composiciones para administracion oral de agentes terapeuticos de peptidos y proteinas. MX2010007462A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL188647A IL188647A0 (en) 2008-01-08 2008-01-08 Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US8029508P 2008-07-14 2008-07-14
PCT/IL2009/000036 WO2009087633A2 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of protein and peptide therapeutic agents

Publications (1)

Publication Number Publication Date
MX2010007462A true MX2010007462A (es) 2010-08-23

Family

ID=40326402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007462A MX2010007462A (es) 2008-01-08 2009-01-08 Metodos y composiciones para administracion oral de agentes terapeuticos de peptidos y proteinas.

Country Status (16)

Country Link
US (3) US20100278922A1 (es)
EP (2) EP2254590B1 (es)
JP (1) JP5432183B2 (es)
KR (1) KR101588066B1 (es)
AU (2) AU2009203530B2 (es)
BR (1) BRPI0906866A2 (es)
CA (2) CA2711556A1 (es)
DK (2) DK2231123T3 (es)
EA (1) EA018461B1 (es)
ES (2) ES2397061T3 (es)
HK (1) HK1148945A1 (es)
IL (3) IL188647A0 (es)
MX (1) MX2010007462A (es)
NZ (1) NZ586374A (es)
WO (2) WO2009087634A2 (es)
ZA (1) ZA201004480B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
EP2451442A4 (en) * 2009-07-09 2014-02-12 Oshadi Drug Administration Ltd MATRIX COMPOSITION COMPOSITIONS, METHODS AND USES
KR102493433B1 (ko) * 2011-05-02 2023-01-27 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
WO2013114371A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
WO2014031837A1 (en) * 2012-08-22 2014-02-27 The Regents Of The University Of California Compositions and methods for enhancing sialic acid levels in tissue
WO2014078435A1 (en) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide
WO2014118774A1 (en) * 2013-01-29 2014-08-07 Oshadi Drug Administration Ltd. Pharmaceutical compositions for oral treatment of diabetes
ES2502691B1 (es) * 2013-09-25 2015-07-07 Sani-Red, S.L. Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos
EP3065717A1 (en) 2013-11-04 2016-09-14 Biopharmx, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers
US9168211B2 (en) * 2014-03-28 2015-10-27 Johnson & Johnson Consumer Inc. Method of making an anhydrous, pigmented composition
KR102418550B1 (ko) * 2015-11-03 2022-07-06 삼성전자주식회사 포토 레지스트 패턴 형성 방법 및 이를 이용한 반도체 장치 제조 방법
WO2017141262A1 (en) * 2016-02-19 2017-08-24 Indian Institute Of Technology, Bombay Orally administrable pharmaceutical preparation containing protein
EP3456859A1 (en) 2017-09-13 2019-03-20 Rolex Sa Protective coating for a complex watch component
CN109819650A (zh) * 2017-09-25 2019-05-28 春布里泽·格奥尔基·格奥尔基耶维奇 具有抗病毒和抗细菌活性的热稳定组合物及其用途
EP3952899A1 (en) * 2019-04-11 2022-02-16 R.P. Scherer Technologies, LLC Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
AU2020406676A1 (en) 2019-12-17 2022-06-23 9286-3620 Québec Inc. Oral delivery systems based on in situ forming protein/polysaccharide coacervates
MX2022009100A (es) 2020-01-28 2022-08-18 Genentech Inc Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer.
JP2023534810A (ja) 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
IL309255A (en) 2021-07-12 2024-02-01 Zidkiyahu Simenhaus Preparations containing proteins, biologically active containing microparticle carriers from cellulose
US20230399362A1 (en) 2022-06-13 2023-12-14 B.A.I. Laboratories, Llc Interleukin-13 binding cyclic oligopeptides and methods of use thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252859A (en) * 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
US6551576B1 (en) * 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
ES2027518A6 (es) 1990-12-18 1992-06-01 Andromaco Lab Procedimiento para la preparacion de nuevas asociaciones no covalentes polisacarido-proteina con actividad farmacologica.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5260002A (en) * 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US5874105A (en) * 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6322765B1 (en) * 1996-02-15 2001-11-27 Wacker-Chemie Gmbh Process for preparing silicon dioxide
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
FR2767718B1 (fr) * 1997-08-28 1999-10-22 Oreal Emulsion eau-dans-huile comprenant de la silice pyrogenee et un alkylether de polysaccharide
JP4792149B2 (ja) * 1997-09-09 2011-10-12 リオトロピック セラピュティックス アイエヌシー． 被覆粒子とその製造法及び使用法
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
FR2773804B1 (fr) * 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
US6656922B2 (en) * 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
CA2371940C (en) * 1999-03-31 2008-07-15 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7195780B2 (en) * 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
DE10001172A1 (de) * 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
JP4631119B2 (ja) * 2000-01-28 2011-02-16 Ｊｓｒ株式会社 疎水化コロイダルシリカの製造方法
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6548264B1 (en) * 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
AU2001273153B2 (en) * 2000-06-29 2005-11-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE50012404D1 (de) * 2000-08-11 2006-05-11 Lohmann Animal Health Gmbh W/o Emulsion Adjuvanszuzammensetzungen für Impstoffen
US20020150621A1 (en) * 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for drug delivery
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
US6698247B2 (en) * 2001-05-04 2004-03-02 Corning Incorporated Method and feedstock for making silica by flame combustion
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20030166509A1 (en) * 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
US20030235619A1 (en) * 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
EP1458365A1 (en) * 2001-12-21 2004-09-22 Celator Technologies Inc. Improved polymer-lipid delivery vehicles
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
EP1474108A2 (en) * 2002-01-09 2004-11-10 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
EP1472351B1 (en) 2002-02-07 2007-06-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
US7244498B2 (en) * 2002-06-12 2007-07-17 Tda Research, Inc. Nanoparticles modified with multiple organic acids
US7090868B2 (en) * 2002-09-13 2006-08-15 University Of Florida Materials and methods for drug delivery and uptake
US7384914B2 (en) * 2003-01-06 2008-06-10 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20040242729A1 (en) * 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
US20070172517A1 (en) 2003-09-17 2007-07-26 Ben-Sasson Shmuel A Compositions capable of facilitation penetration across a biological barrier
NZ546379A (en) * 2003-10-31 2010-04-30 Teva Pharma Nanoparticles for drug delivery
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
MXPA06011871A (es) 2004-04-15 2007-10-08 Chiasma Inc Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
US7288134B2 (en) * 2004-09-10 2007-10-30 International Business Machines Corporation Dumbbell-like nanoparticles and a process of forming the same
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
WO2006044660A2 (en) * 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
WO2006062506A1 (en) 2004-12-03 2006-06-15 Enzrel, Inc. Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds
NZ565662A (en) * 2005-08-09 2010-10-29 Univ Sunderland Fingerprint analysis using mass spectrometry
ES2761937T3 (es) * 2005-10-24 2020-05-21 Magsense Life Sciences Inc Método para preparar micropartículas recubiertas con polímero
US20070104778A1 (en) * 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
WO2008048288A2 (en) * 2005-11-09 2008-04-24 Montana State University Novel nanoparticles and use thereof
JP2009518289A (ja) * 2005-11-21 2009-05-07 メディバス エルエルシー 高分子の送達用ポリマー粒子および使用方法
US20070184076A1 (en) * 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
JP2009533471A (ja) * 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
EP2451442A4 (en) * 2009-07-09 2014-02-12 Oshadi Drug Administration Ltd MATRIX COMPOSITION COMPOSITIONS, METHODS AND USES

Also Published As

Publication number Publication date
AU2009203530B2 (en) 2013-10-24
WO2009087633A2 (en) 2009-07-16
WO2009087633A3 (en) 2010-03-11
US20100278922A1 (en) 2010-11-04
ES2398015T3 (es) 2013-03-13
IL188647A0 (en) 2008-11-03
EP2231123A4 (en) 2011-09-07
EA018461B1 (ru) 2013-08-30
JP5432183B2 (ja) 2014-03-05
AU2009203530A1 (en) 2009-07-16
US9949924B2 (en) 2018-04-24
DK2231123T3 (da) 2013-02-04
IL206835A0 (en) 2010-12-30
AU2009203529A1 (en) 2009-07-16
IL206834A0 (en) 2010-12-30
EP2231123A2 (en) 2010-09-29
WO2009087634A3 (en) 2010-01-07
JP2011509287A (ja) 2011-03-24
CA2711554A1 (en) 2009-07-16
NZ586374A (en) 2011-10-28
US20100297245A1 (en) 2010-11-25
EP2254590A4 (en) 2012-01-25
WO2009087634A2 (en) 2009-07-16
IL206834A (en) 2015-09-24
EP2254590B1 (en) 2012-10-10
EP2254590A2 (en) 2010-12-01
US8936786B2 (en) 2015-01-20
KR20100119541A (ko) 2010-11-09
EP2231123B1 (en) 2012-10-24
IL206835A (en) 2017-09-28
EA201070827A1 (ru) 2010-12-30
BRPI0906866A2 (pt) 2019-02-26
ZA201004480B (en) 2011-09-28
CA2711556A1 (en) 2009-07-16
DK2254590T3 (da) 2013-01-28
US20150147399A1 (en) 2015-05-28
HK1148945A1 (en) 2011-09-23
AU2009203529B2 (en) 2013-09-05
ES2397061T3 (es) 2013-03-04
KR101588066B1 (ko) 2016-01-22
CA2711554C (en) 2017-01-03

Similar Documents

Publication Publication Date Title
MX2010007462A (es) Metodos y composiciones para administracion oral de agentes terapeuticos de peptidos y proteinas.
MX2009005727A (es) Nanoparticulas de entidad anfifilica.
EA200870219A1 (ru) Стабилизированные сукцинатом витамина е фармацевтические композиции, способы их получения и применения
EA200600877A1 (ru) Наночастицы для доставки лекарств
WO2005112633A3 (en) Compounds and compositions for delivering active agents
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2008105773A3 (en) System for targeted delivery of therapeutic agents
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
PL2081547T3 (pl) Postać galenowa do podawania składników czynnych poprzez śluzówkę
MX2010007150A (es) Formulaciones del factor de von-willebrand recombinante.
AU2008347158A8 (en) Oral pharmaceutical dosage forms
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer
WO2006017251A3 (en) Compositions for delivering peptide yy and pyy agonists
RS52831B (en) THIN BUPRENORPHINE TILES FOR DRUG REPLACEMENT THERAPY
MX2010002409A (es) Composiciones y metodos para la distribucion de farmacos escasamente solubles.
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
MXPA05012278A (es) Composiciones para suministrar peptido yy y combatientes pyy.
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
EA200802350A2 (ru) Система доставки лекарств
WO2008150495A3 (en) Vwf aptamer formulations and methods for use
EP2131849A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER
DE602004023093D1 (de) N mit einem abgabemittel in mikronisierter form
WO2008070141A3 (en) Compositions for delivery of therapeutic agents
HK1120417A1 (en) Stable nanoparticle formulations

Legal Events

Date Code Title Description
FG Grant or registration